Company intelligence / Profile preview

Giaconda Limited

Sydney, New South Wales, Australiabbr.com ↗

Ownership: Public · ASX:GIA
Development stage: Phase 3

Overview

Giaconda developed novel combinations of known compounds for gastrointestinal conditions. Their lead product Myoconda completed a Phase III trial for Crohn's Disease with 213 patients across 20 centers in Australia. Hepaconda showed improvement in liver function in Phase II trials.

Therapeutic areas: GastroenterologyInfectious Diseases
Modalities: Drug combinations
Industry: Biotech

Drug pipeline

2 assets

bezafibrate

1 more asset in the full pipeline.

Request access →

Partnerships

Forest Laboratories (non-binding letter of intent for UK and Irish market)Pharmacia (option agreement)RedHill Biopharma (acquired three products)Ind Swift Laboratories (supply and manufacture agreement for Myoconda)

Beyond the preview

Go deeper on Giaconda Limited.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Giaconda Limited.

Explore the full profile